Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women’s health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally.
infoHologic is a large cap stock with a total market cap of 18.54B.
infoThey trade on the NASDAQ and had their IPO 33 years and 5 months ago.
infoHologic currently employs 6944 people.
infoAs of Wednesday, Aug 23 2023, Hologic’s share price is $75.31.
News Relating to Hologic
Zacks Investment Research
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Tuesday Aug 22 2023 at 19:32
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock’s prospects.
Zacks Investment Research
Hologic’s (HOLX) Q3 Earnings Beat Estimates, 2023 View Up
Tuesday Aug 01 2023 at 12:40
Strength in Breast Health and GYN Surgical drives Hologic’s (HOLX) Q3 performance.
CNBC Television
Hologic CEO on capital expenditures and the business post-Covid
Tuesday Aug 01 2023 at 12:14
Hologic CEO Steve MacMillan joins ‘Squawk on the Street’ to discuss MacMillan’s expectations for the company post-Covid, how the CEO is allocating capital, and more.
Seeking Alpha
Hologic, Inc. (HOLX) Q3 2023 Earnings Call Transcript
Monday Jul 31 2023 at 23:14
Hologic, Inc. (NASDAQ:HOLX ) Q3 2023 Earnings Conference Call July 31, 2023 4:30 PM ET Company Participants Ryan Simon – Vice President, Investor Relations Stephen MacMillan – Chairman, President and Chief Executive Officer Karleen Oberton – Chief Financial Officer Conference Call Participants Patrick Donnelly – Citi Michael Matson – Needham & Company Jack Meehan – Nephron Research Vijay Kumar – Evercore ISI Timothy Daley – Wells Fargo Tejas Savant – Morgan Stanley Puneet Souda – Leerink Partners Anthony Petrone – Mizuho Group Ryan Zimmerman – BTIG Andrew Cooper – Raymond James Andrew Brackmann – William Blair Elizabeth Garcia – UBS Operator Good afternoon, and welcome to the Hologic’s Third Quarter Fiscal 2023 Earnings Conference Call. My name is Cynthia, and I am your operator for today’s call.
Zacks Investment Research
Hologic (HOLX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Monday Jul 31 2023 at 20:09
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research
Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates
Monday Jul 31 2023 at 18:38
Hologic (HOLX) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.95 per share a year ago.
Market Watch
Hologic stock falls nearly 4% after company’s revenue drop on lower COVID-related sales
Monday Jul 31 2023 at 16:50
Shares of Hologic Inc. HOLX, -1.57% dropped more than 3% in the aftermarket Monday after the medical technology company topped Wall Street estimates for its fiscal third quarter and tweaked its guidance for the fiscal year and for the fiscal fourth quarter. Hologic lost $40.5 million, or 16 cents a share, in the quarter, versus earnings of $228.4 million, or 90 cents a share, in the year-ago period.
24/7 Wall Street
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
Monday Jul 24 2023 at 22:43
A financial advisor can help you understand the advantages and disadvantages of investment properties.
Zacks Investment Research
Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings
Monday Jul 24 2023 at 10:51
Hologic’s (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.
InvestorPlace
3 Top Analyst Picks Worth Your Attention Now
Monday Jul 17 2023 at 18:50
Diving into a world where an analyst picks stocks may feel like exploring a complex maze. These analysts, akin to dedicated scholars of the stock market, offer their expertise to investors in pointing out potential pathways for investors.
Business Wire
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2023 on Monday, July 31, 2023
Wednesday Jul 05 2023 at 08:08
MARLBOROUGH, Mass.–(BUSINESS WIRE)—- $HOLX #earnings–Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (877) 400-0505 (in the United States and Canada) or +1 (773) 305-6865 (for international callers) and referencing.
Seeking Alpha
Hologic: Additional Critical Factors Forming Bullish Thesis, Reiterate Buy
Saturday Jul 01 2023 at 05:25
Hologic continues to present with attractive business economics and robust fundamentals ex-Covid. There are additional critical factors to consider, including positive sentiment and price studies. Investors look to be bullish on HOLX based on the culmination of studies presented in this report.
Zacks Investment Research
Hologic (HOLX) Gains From Core Businesses’ Growth, Innovation
Monday Jun 19 2023 at 10:13
Hologic’s (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.
Zacks Investment Research
Here’s Why You Should Invest in Hologic (HOLX) Stock Now
Thursday Jun 15 2023 at 09:17
Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.
Zacks Investment Research
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Friday Jun 09 2023 at 10:12
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research
Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?
Monday Jun 05 2023 at 15:26
The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.
Zacks Investment Research
Why Is Hologic (HOLX) Down 6.3% Since Last Earnings Report?
Wednesday May 31 2023 at 12:46
Hologic (HOLX) reported earnings 30 days ago. What’s next for the stock?
Forbes
Stocks This Week: Buy Hologic
Monday May 29 2023 at 13:32
June has been a strong month for this stock.
Zacks Investment Research
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Monday May 29 2023 at 10:05
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock’s prospects.
Zacks Investment Research
3 Medical Instruments Stocks to Buy Amid Industry Challenges
Thursday May 25 2023 at 10:46
The Zacks Medical – Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most.
Zacks Investment Research
Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test
Monday May 22 2023 at 12:05
Hologic’s (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.
Zacks Investment Research
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
Wednesday May 17 2023 at 12:48
Hologic (HOLX) and Eagles’ CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Zacks Investment Research
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Tuesday May 16 2023 at 10:39
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock’s prospects.
Investors Business Daily
10 Companies Are Doing So Well Even Analysts Are Amazed
Friday May 12 2023 at 08:00
Corporate profits in the S&P 500 are coming in strong. So strong, in fact, that some keep blowing away even the analysts’ expectations.
Zacks Investment Research
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Friday May 05 2023 at 10:40
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
Wednesday May 03 2023 at 12:55
Investors interested in Medical – Instruments stocks are likely familiar with Hologic (HOLX) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research
Hologic’s (HOLX) Q2 Earnings Beat Estimates, 2023 View Up
Tuesday May 02 2023 at 13:43
The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic’s (HOLX) Q2 revenues.
Seeking Alpha
Hologic, Inc. (HOLX) Q2 2023 Results – Earnings Call Transcript
Monday May 01 2023 at 21:39
Hologic, Inc. (NASDAQ:HOLX ) Q2 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Ryan Simon – VP, IR Stephen MacMillan – Chairman, President and CEO Karleen Oberton – CFO Conference Call Participants Patrick Donnelly – Citi Tim Daley – Wells Fargo Casey Woodring – JPMorgan Anthony Petrone – Mizuho Group Elizabeth Garcia – UBS Andrew Cooper – Raymond James Jack Meehan – Nephron Research Puneet Souda – SVB Securities Jack Meehan – Nephron Research Max Masucci – Cowen & Company Tejas Savant – Morgan Stanley Andrew Brackmann – William Blair. John Murphy – Bank of America Vijay Kumar – Evercore ISI Navann Ty Dietschi – BNP Paribas Exane Operator Good afternoon, and welcome to the Hologic Second Quarter Fiscal 2023 Earnings Conference Call.
Zacks Investment Research
Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Monday May 01 2023 at 19:46
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research
Hologic (HOLX) Surpasses Q2 Earnings and Revenue Estimates
Monday May 01 2023 at 19:01
Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $2.07 per share a year ago.
Hologic Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Hologic’s Altman Z-score is 4.08 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Hologic Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 2 insiders have sold $997.36K of common stock in Hologic on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Hologic’s Income Quality of 1.39 is greater than its Industry Group of 0.68 (104.4% greater)
Hologic’s Income Quality of 1.39 is greater than its Major Industry Group of 0.71 (95.8% greater)
Hologic’s Income Quality of 1.39 is greater than its Sector of 0.75 (85.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Hologic’s Current Ratio of 4.42 is greater than its Industry Group of 3.36 (31.5% greater)
Hologic’s Current Ratio of 4.42 is greater than its Major Industry Group of 3.13 (41.2% greater)
Hologic’s Current Ratio of 4.42 is greater than its Sector of 2.6 (70.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (38.29 & -1.02)
Cannot compare a negative PE Ratio (38.29 & -0.58)
Cannot compare a negative PE Ratio (38.29 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Hologic’s PB Ratio of 3.58 is greater than its Industry Group of 1.9 (88.4% greater)
Hologic’s PB Ratio of 3.58 is greater than its Major Industry Group of 1.93 (85.5% greater)
Hologic’s PB Ratio of 3.58 is greater than its Sector of 1.62 (121.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Hologic’s ROE of 0.09 is greater than its Industry Group of -0.26 (134.6% greater)
Hologic’s ROE of 0.09 is greater than its Major Industry Group of -0.09 (200.0% greater)
Hologic’s ROE of 0.09 is greater than its Sector of -0.03 (400.0% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Hologic’s ROCE of 0.09 is greater than its Industry Group of -0.27 (133.3% greater)
Hologic’s ROCE of 0.09 is greater than its Major Industry Group of -0.14 (164.3% greater)
Hologic’s ROCE of 0.09 is greater than its Sector of -0.04 (325.0% greater)
Derived from SEC.GOV filing dataopen_in_new